Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

NCT07778836 is registered in ClinicalTrials.gov with Larimar Therapeutics, Inc. as lead sponsor.

NCT NCT07778836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07778836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
Lead sponsor
Larimar Therapeutics, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
October 26, 2026
Completion date
December 31, 2029
Enrollment
150 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

friedreich ataxia, friedreich's ataxia